Simple Summary Pancreatic ductal adenocarcinoma (PDAC) is the most common type of
pancreatic cancer, responsible for the majority of cases and ranking seventh as a leading …

Poly (ADP-ribose) polymerase inhibitors (PARPis) have demonstrated clinical activity in
patients with BRCA1 and/or BRCA2 mutated breast, ovarian, prostate, and pancreatic …

Cancer is a very heterogeneous disease, and uncontrolled cell division is the main
characteristic of cancer. Cancerous cells need a high nutrition intake to enable aberrant …

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and lethal malignancy with a
high rate of recurrence and a dismal 5‐year survival rate. Contributing to the poor prognosis …

Pancreatic ductal adenocarcinoma (PDAC) is the seventh leading cause of cancer death
worldwide; most of cases are sporadic, however about 5% to 10% report a hereditary …

At least 5% of cancer diagnoses are attributed to a causal pathogenic or likely pathogenic
germline genetic variant (hereditary cancer syndrome—HCS). These individuals are …

Hereditary breast and ovarian cancer is caused by a germline mutation in BRCA1 or BRCA2
genes. The frequency of germline BRCA1/2 gene mutation carriers and the ratio of germline …

Simple Summary With the mortality rate of pancreatic cancer predicted to rise over the
coming years, it is essential that effective treatment strategies are developed as soon as …

Breast cancer susceptibility gene 2 (BRCA2) is the main gene associated with hereditary
breast cancers. However, a mutation in BRCA2 has also been found in other tumors, such …

Pancreatic cancer is a malignant disease characterized by low survival and high recurrence
rate, whose patients are mostly at the stage of locally advanced or metastatic disease when …